The SVF-2 presents a major step forward for cellular therapy.
The SVF-2 uniquely harvests and isolates a patient’s own stromal and vascular cells, including stromal progenitor cells, to help control pain, reduce inflammation, and repair inflamed tissues in the osteoarthritic knee. FDA Phase II clinical trials for this minimally invasive procedure have shown no serious adverse events and significant improvements in pain, stiffness and function (see results of the clinical study here: AJSM Phase IIb ).
Our modular tissue-processing platform enables point-of-care therapy for a broad range of indications. By reducing an entire cell-processing facility to a single disposable device, physicians can extract and process adipose tissue in real time using proven scientific methods, controls, and reagents. This platform provides scalable cell processing for hospitals, medical practices and other surgical or clinical settings.
Clinical trials evaluating the effectiveness of the SVF-2 in treating peripheral vascular disease in both small & large vessels, diabetic ulcers, and volume augmentation have already been completed, with more coming soon. More information about these trials can be found here.
